An Update on Pulmonary Hypertension in Coronavirus Disease-19 (COVID-19)
Coronavirus 19 disease (COVID-19) continues to be a pandemic with global implications. Respiratory system involvement is the most common manifestation in symptomatic patients. In this literature review, we describe the diagnosis, management, and implications of pulmonary hypertension (PH) among patients with COVID-19. We defined pulmonary hypertension as increasing mean pulmonary artery pressure (mPAP) of ≥ 25 mm Hg at rest. In our literature search, we identified 4 articles with details on pulmonary hypertension. Among these, two reported various echocardiographic details for diagnosing pulmonary hypertension. In 1 study evidence of pulmonary hypertension was noted in 13.4% of patients. Patients with severe COVID-19 were reported to have a higher proportion of pulmonary hypertension as compared to mild COVID-19 disease [22% vs 2%]. Elevated pulmonary artery systolic pressure was significant in predicting mortality. COVID-19 patients with chronic obstructive pulmonary disease, congestive heart failure, myocardial injury, pulmonary embolism, and prior pulmonary hypertension were at a higher risk of worsening pulmonary hypertension. Multiple mechanisms for developing pulmonary hypertension that have been postulated are i) concomitant worsening myocardial injury, ii) cytokine storm, endothelial injury, hypercoagulability attributing to development of venous thromboembolism, iii) and the presence of thrombotic microangiopathy. Among patients with severe COVID-19 disease and pulmonary hypertension, complications including acute respiratory distress syndrome, acute myocardial injury, the requirement of intensive care unit admission, the requirement of mechanical ventilation, and mortality are higher.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:91 |
|---|---|
| Enthalten in: |
Acta bio-medica : Atenei Parmensis - 91(2020), 4 vom: 10. Nov., Seite e2020155 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mishra, Ajay [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 08.03.2021 Date Revised 16.07.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.23750/abm.v91i4.10698 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320862666 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320862666 | ||
| 003 | DE-627 | ||
| 005 | 20231225174549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.23750/abm.v91i4.10698 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM320862666 | ||
| 035 | |a (NLM)33525228 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mishra, Ajay |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An Update on Pulmonary Hypertension in Coronavirus Disease-19 (COVID-19) |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.03.2021 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Coronavirus 19 disease (COVID-19) continues to be a pandemic with global implications. Respiratory system involvement is the most common manifestation in symptomatic patients. In this literature review, we describe the diagnosis, management, and implications of pulmonary hypertension (PH) among patients with COVID-19. We defined pulmonary hypertension as increasing mean pulmonary artery pressure (mPAP) of ≥ 25 mm Hg at rest. In our literature search, we identified 4 articles with details on pulmonary hypertension. Among these, two reported various echocardiographic details for diagnosing pulmonary hypertension. In 1 study evidence of pulmonary hypertension was noted in 13.4% of patients. Patients with severe COVID-19 were reported to have a higher proportion of pulmonary hypertension as compared to mild COVID-19 disease [22% vs 2%]. Elevated pulmonary artery systolic pressure was significant in predicting mortality. COVID-19 patients with chronic obstructive pulmonary disease, congestive heart failure, myocardial injury, pulmonary embolism, and prior pulmonary hypertension were at a higher risk of worsening pulmonary hypertension. Multiple mechanisms for developing pulmonary hypertension that have been postulated are i) concomitant worsening myocardial injury, ii) cytokine storm, endothelial injury, hypercoagulability attributing to development of venous thromboembolism, iii) and the presence of thrombotic microangiopathy. Among patients with severe COVID-19 disease and pulmonary hypertension, complications including acute respiratory distress syndrome, acute myocardial injury, the requirement of intensive care unit admission, the requirement of mechanical ventilation, and mortality are higher | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Lal, Amos |e verfasserin |4 aut | |
| 700 | 1 | |a Sahu, Kamal Kant |e verfasserin |4 aut | |
| 700 | 1 | |a George, Anu Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Sargent, Jennifer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta bio-medica : Atenei Parmensis |d 2002 |g 91(2020), 4 vom: 10. Nov., Seite e2020155 |w (DE-627)NLM12090733X |x 2531-6745 |7 nnns |
| 773 | 1 | 8 | |g volume:91 |g year:2020 |g number:4 |g day:10 |g month:11 |g pages:e2020155 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.23750/abm.v91i4.10698 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 91 |j 2020 |e 4 |b 10 |c 11 |h e2020155 | ||